Bender Catherine M, Gentry Amanda L, Brufsky Adam M, Casillo Frances E, Cohen Susan M, Dailey Meredith M, Donovan Heidi S, Dunbar-Jacob Jacqueline, Jankowitz Rachel C, Rosenzweig Margaret Q, Sherwood Paula R, Sereika Susan M
Clinical and Translational Science Institute.
Department of Health and Community Systems, School of Medicine.
Oncol Nurs Forum. 2014 May;41(3):274-85. doi: 10.1188/14.ONF.274-285.
PURPOSE/OBJECTIVES: To comprehensively assess the patient and illness or treatment factors that may predict nonadherence to adjuvant endocrine therapy and to explore whether an interaction occurs between these factors in women with breast cancer.
Repeated-measures design.
The Outpatient Services of the Women's Cancer Program at the University of Pittsburgh Cancer Institute and participants' homes.
91 women with early-stage breast cancer who received endocrine therapy.
Adherence was assessed continuously for the first 18 months of endocrine therapy. Patient and illness or treatment factors were assessed at four time points (Time 1 to Time 4). Time 1 (baseline) was within two weeks prior to the initiation of endocrine therapy. Times 2-4 occurred at six-month intervals, as many as 18 months after Time 1.
Adherence, patient factors, and illness or treatment factors.
Adherence to endocrine therapy declined significantly during the first 18 months of treatment in women with breast cancer. The presence of negative mood and symptoms before starting treatment predicted nonadherence to endocrine therapy over time. Perceptions of financial hardship, symptoms, disease stage, and more complex medication regimens intensified the effect of negative mood on adherence over time.
Women with breast cancer may be at risk for nonadherence to prescribed endocrine therapy if they experience depression or anxiety and symptoms prior to initiating therapy.
Oncology nurses should be alert to women with breast cancer who are depressed or anxious or who are experiencing symptoms. Management of negative mood and symptoms may result in better adherence.
目的/目标:全面评估可能预测辅助内分泌治疗依从性的患者、疾病或治疗因素,并探讨这些因素在乳腺癌女性患者中是否存在相互作用。
重复测量设计。
匹兹堡大学癌症研究所女性癌症项目门诊服务部及参与者家中。
91例接受内分泌治疗的早期乳腺癌女性患者。
在内分泌治疗的前18个月持续评估依从性。在四个时间点(时间1至时间4)评估患者、疾病或治疗因素。时间1(基线)在内分泌治疗开始前两周内。时间2至4每隔六个月进行一次,在时间1后长达18个月。
依从性、患者因素以及疾病或治疗因素。
乳腺癌女性患者在治疗的前18个月内分泌治疗依从性显著下降。开始治疗前存在负面情绪和症状预示着随着时间推移内分泌治疗依从性不佳。随着时间推移,经济困难、症状、疾病分期和更复杂的药物治疗方案的认知加剧了负面情绪对依从性的影响。
乳腺癌女性患者如果在开始治疗前经历抑郁或焦虑以及出现症状,可能存在不依从规定内分泌治疗的风险。
肿瘤护士应警惕患有抑郁、焦虑或出现症状的乳腺癌女性患者。管理负面情绪和症状可能会提高依从性。